Cloning, expression, monoclonal antibody preparation of human gene NBEAL1 and its application in targeted imaging of mouse glioma

Nano Biomedicine and Engineering

Volumn 1, Issue 1, 2009, Pages 50-56

  Bao, Chenchen ^a,b,c   Yang, Hao ^b,c   Sheng, Ping ^a   Chen, Juxiang ^a   Song, Hua ^b,c   Ding, Xuehua ^a   Liu, Bin ^b,c   Lu, Yicheng ^a   Hu, Guohan ^a   Cui, Daxiang ^b,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Clone; Expression; Glioma; Monoclonal antibody; Nbeal1

Indexed keywords

EID: 79951984863     PISSN: None     EISSN: 21505578     Source Type: Journal    
DOI: 10.5101/nbe.v1i1.p50-56     Document Type: Article

References (31)

1. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neuro 2006; 2: 494-503.
2. Lu C, Shervington A. Chemoresistance in gliomas. Mol Cell Biochem 2008; 312: 71-80.
3. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK. The WHO classification of tumors of the nervous system. J Neuropath Exp Neur 2002; 61: 215.
4. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system: International Agency for Research on Cancer Lyon, France, 2007.
5. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta neuropathologica 2007; 114: 97-109
6. Martin-Villalba A, Okuducu AF, von Deimling A. The evolution of our understanding on glioma. Brain Pathology 2008; 18: 455-463.
7. Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME. Molecular targets of glioma invasion. Cell Mol Life Sci 2007; 64: 458-478.
8. Grier JT, Batchelor T. Lowgrade gliomas in adults. The Oncologist 2006; 11: 681.
9. McKnight TR, von dem Bussche MH, Vigneron DB, Lu Y, Berger MS, McDermott MW. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002; 97: 794-802.
10. Galanaud D, Chinot O, Nicoli F, Confort-Gouny S, Le Fur Y, Barri Attarian M, Ranjeva JP, Fuent S, Viout P, Figarella-Branger D. Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from lowgrade glioma. J Nneurosurg 2003; 98:269-276.
11. Jeuken JWM, Deimling AV, Wesseling P. Molecular pathogenesis of oligodendroglial tumors. J Neuro-oncol 2004; 70: 161-181.
12. Chen J, Lu Y, Xu J, Huang Y, Cheng H, Hu G, Luo C, Lou M, Cao G, Xie Y, Ying K. Identification and characterization of NBEAL1, a novel human neurobeachin-like 1 protein gene from fetal brain, which is up regulated in glioma. Brain Res Mol Brain Res 2004; 125: 147-155.
13. Jeong H, Chang AM and Melloch MR. The Kondo Effect in an Artificial Quantum Dot Molecule. Science 2001; 293: 2221-2223.
14. Li XQ, Wu YW, Steel D, Gammon D, Stievater TH, Katzer DS. An all-optical quantum gate in a semiconductor quantum dot. Science 2003; 301: 809-811.
15. Lu W, Ji ZQ, Pfeiffer L, West KW, Rimberg AJ. Real-time detection of electron tunnelling in a quantum dot. Nature 2003; 423: 422-425.
16. 2 core/shell luminescent composite nano particles. Acta Chimi Sin 2007; 65:561-565.
17. Kaul Z, Yaguchi T, Kaul SC, Hirano T, Wadhwa R and Taira K. Mortalin imaging in normal and cancer cells with quantum dot immunoconjugates. Cell Res 2003; 13: 503-507.
18. Medintz IL, Uyeda HT, Goldman ER and Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nature Mater 2005; 4: 435-446.
19. Shao J, You X, Gao F, He R, Cui D. Labeling of quantum dots with streptavidin and its bioactivity measurement. Chinese J Anal Chem 2006; 34:1625-1628.
20. He R, You X, Shao J, Gao F, Pan B, Cui D. Core/shell fluorescent magnetic silica-coated composite nanoparticles for bioconjugation. Nanotechnology 2007; 18, 315601.
21. Cui D. Pan B. Zhang H, Wu R, Wang J, Asahi T, et al. Self/Assembly of Quantum Dots and Carbon Nanotubes For Ultrasensitive DNA and Antigen Detection. Anal Chem 2008; 80: 7996-8001.
22. Li Z, Huang P, He R, Lin J, Yang S, Zhang X, et al. Aptamer-conjugated dendrimer-modified quantum dots for cancer cell targeting and imaging. Mater Lett 2010; 64: 375-378.
23. Cui D, Gao T, Jin D, Sun T, Tian F, Estrada GG, et al. Characterization of BRCAA1 and its clinical significance. Cancer Epid. Biomarker Prev 2004; 13: 1336-1445.
24. Jogl G, Shen Y, Gebauer D, Li J, Wiegmann K, Kashkar H, Kroke M, et al. Crystal structure of the BEACH domain reveals an unusual fold and extensive association with a novel PH domain. EMBO J 2002; 21: 4785-4795.
25. De Lozanne A. The Role of BEACH Proteins in Dictyostelium. Traffic 2003; 4: 6.
26. Su Y, Balice-Gordon RJ, Hess DM, Landsman DS, Minarcik J, Golden J, et al. Neurobeachin is essential for neuromuscular synaptic transmission. J Neurosci 2004; 24: 3627-3636.
27. Wang X, Herberg FW, Laue MM, Wullner C, Hu B, Petrasch-Parwez E, et al. Neurobeachin: A protein kinase Aanchoring, beige/Chediak-higashi protein homolog implicated in neuronal membrane traffic. J Neurosci 2000; 20: 8551-8565.
28. O'Neal J, Gao F, Hassan A, Monahan R, Barrios S, Lee I, et al. Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma. Exp Hematol 2009; 37: 234-244.
29. Yip S, Iafrate AJ, Louis DN. Molecular Diagnostic Testing in Malignant Gliomas: A Practical Update on Predictive Markers. J Neuropathol Exp Neurol 2008; 67: 1-15.
30. Hesson LB, Krex D, Latif F. Epigenetic markers in human gliomas: prospects for therapeutic intervention. Expert Rev Neurother 2008, 8, 1475-1496.
31. Pc B, Schthauer BW, Vogel FS. Surgical Pathology of the Nervous System and its coverings. Philadelphia: churchill Livingstone, 2002.